Normalization to external reference for reduction of technical variation
Background
Mitigation of technical variability is a key aspect in relating proteomic biomarkers to clinical endpoints. A primary source of variability comes from inherent issues in the actual technology used to measure the protein levels in a sample, but additional variability can come from many different sources, including plate differences, sample handling differences, and study or cohort differences. Without bridging samples, these different sources of variation can lead to difficulties in combining different cohorts and across studies longitudinally, preventing researchers from sharing data easily. Here, we present results for normalization to an external reference population, which allows us to combine datasets without the need for bridging samples.
Methods
SomaLogic performs a series of steps to standardize the SomaScan® Assay data. These steps are hybridization normalization, plate scaling and calibration, and the adaptive normalization by maximum likelihood (ANML), which normalizes SomaScan EDTA plasma measurements to a healthy U.S. population reference. Because this normalization technique does not require bridging samples, it can be used to combine data from different times and sources. The impact of this type of normalization is quantified through CV calculations over multiple runs and time points. As an example, we demonstrate the benefits of this method on age and sex as clinical endpoints.
Results
The median coefficient of variation (CV) on raw SomaScan data is 22.4%, which drops to 5.3% after all standardization steps and ANML normalization are applied. Longitudinally, the median CV after ANML normalization remained steady at 5.5% across all cohorts that were run between June of 2020 and May of 2023. Examination of analytes related to age and sex confirmed that known biomarkers were more easily identified after ANML normalization was applied.
Conclusions
Use of a reference population allows for bridging across varied cohorts and studies, which allows for increased use of SomaScan data
among researchers using proteomics for biomarker discovery and clinical development.
Authors
Y. Hagar
D. Maxwell
C. Jamison
M. Westacott
D. Perry
SomaLogic Operating Co., Inc., Boulder, CO, USA
Learn more by downloading this poster
More posters
PosterOptimizing biomarker discovery with focus on low coefficient of variation in large-scale proteomics
Coefficients of variation (CV) describe innate technical variation in high throughput molecular measurement platforms and are a standard metric for characterizing and monitoring assay precision. Median CVs range from ~4.5% to 18.0% for immunoassay technology, 1 up to >30% for mass spectrometry,2 ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay (Figure 1). Large CVs can cause technical variability to overwhelm biological signal.
PosterA proteomic predictor of conversion from mild cognitive impairment to dementia with potential utility in enhancing productivity of emerging clinical trials
A significant proportion of individuals with mild cognitive impairment (MCI) develop dementia, with annual conversion rates exceeding 10%. Earlier dementia diagnosis and intervention can improve outcomes, and new disease-modifying drugs are being repositioned for the preclinical stages of illness.
PosterQuantitative immunology protein panel built on the SomaScan Assay platform
The SomaScan® assay is a highly multiplexed proteomic assay that uses SOMAmer® reagents to detect proteins in various biological samples. The latest version of the SomaScan assay allows researchers to measure over 11,000 proteins in human blood. The SomaScan assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer reagent abundance quantified using DNA microarrays.